Made for the UK. Informed by evidence.Our editorial promise
INTERNATIONAL CONTEXT FOR UK READERS

Obesity care in Africa

Our pages on South Africa, Kenya and Egypt help UK readers interpret international obesity-treatment information. They use each country's regulator material and state where funding evidence is incomplete. Local authorisation does not establish UK availability, and these guides are not international purchasing recommendations.

Check the date of the evidence

An older warning can remain online after newer product approvals. Read it for the safety issue it describes, then check current product information before concluding that a medicine is or is not authorised.

Keep evidence gaps visible

A product assessment cannot establish public funding, retail price or stock. Where public documents leave those questions unanswered, we say so. UK readers should use our UK guide for the NHS and private-care decisions relevant to them.

Explore the country guides

3 guides

South Africa ↗

South Africa's current product information is essential: older online statements predate later weight-management approvals. SAHPRA's approved documents and its more recent enforcement notices should be read for their different purposes.

Read the country guide →

Kenya ↗

Kenya's Pharmacy and Poisons Board publishes medicine information and tools for verifying licensed pharmacy premises. Those checks provide a firmer starting point than an online stock claim, while funding and availability still need local confirmation.

Read the country guide →

Egypt ↗

Egypt's Drug Authority publishes a Wegovy assessment report and separate national formulary information on semaglutide. Reading the product and indication together is essential; an ingredient name alone does not describe the approved treatment.

Read the country guide →